One of the most important ongoing first-in-human trials is the SHERPA trial, a combination therapy of SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in metastatic KRAS-mutated cancers [135]. This evidence concerns the gene KRAS and cancer.